about
Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analysesEconomic considerations in the management of Alzheimer's diseaseMemantine for dementiaQuetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trialFailures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insultsMemantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapsesLong-term course and effectiveness of combination therapy in Alzheimer diseasePerispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanismTNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot studyOverview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal CompoundsNMDA Receptor Function During Senescence: Implication on Cognitive PerformanceAnti-dementia medications: current prescriptions in clinical practice and new agents in progressEmerging pharmacologic treatment options for fragile X syndromeAlzheimer's therapeutics: translation of preclinical science to clinical drug developmentα7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumA practical algorithm for managing Alzheimer's disease: what, when, and why?Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysisNMDA receptor modulators: an updated patent review (2013-2014)Parallels between major depressive disorder and Alzheimer's disease: role of oxidative stress and genetic vulnerabilityThe BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical reviewMemantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's diseaseVitamin Supplementation as an Adjuvant Treatment for Alzheimer's DiseaseOral Delivery of Protein Drugs Bioencapsulated in Plant CellsStroke, dementia, and drug deliveryThe potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's diseaseEvidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's DiseaseThe chemical biology of clinically tolerated NMDA receptor antagonistsGlutamate receptor ion channels: structure, regulation, and functionA chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerizationMapping the high-affinity binding domain of 5-substituted benzimidazoles to the proximal N-terminus of the GluN2B subunit of the NMDA receptorEffects of memantine on mitochondrial function.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Advances in the treatment of anxiety: targeting glutamate.Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantinePotential therapeutic interventions for fragile X syndromePharmacodynamics of memantine: an update.Molecular targets for treating cognitive dysfunction in schizophrenia.Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.Hippocampal Gαq/₁₁ but not Gαo-coupled receptors are altered in aging.Current neuroimaging techniques in Alzheimer's disease and applications in animal models
P2860
Q21134547-8F67D9F7-056F-4214-9A5F-8E91F333291AQ22241448-262C7AF7-17A7-439A-8F63-1A13BEFDCED4Q22252980-B162637C-2089-4CE5-84A8-C4A367936DA9Q24555726-4F1F1FEB-B902-4DD9-A222-E1D4E0AEA47BQ24558984-7A3DAC04-5617-4692-AE71-D7C52810C0F5Q24619395-FE9C1AC1-73FD-4A04-9A21-E9729BD59277Q24642161-22376B99-DE4F-488E-8BD8-64DFB539E0B1Q24652684-C8D89A3D-E675-42C8-8A1A-FEEAE10AA0C1Q24681139-0F946D5F-0BCD-49A8-A10B-A1DAE4141215Q26749061-15D7147C-B74F-4F32-A7F7-1652B48165E9Q26770902-56E375D3-217E-4B52-BDC0-C14804A1596BQ26795400-2B8A3334-7FF1-400D-B6C3-0CD7F2A7CC16Q26829152-6162B4B7-54F2-456A-9226-F5281A79597FQ26829267-A84C0257-FAA6-4F32-8BFB-6EFBA6A6A9D0Q26852967-1CF9A1E6-FBBE-46B4-956D-41147E43ED3DQ26859831-C2C8FE07-2FF7-4D72-9C4A-1DB243E0CED9Q26861399-4C557C16-E7DC-4D06-AFD5-007FD1EF7201Q26997407-BAF5681A-38DD-4FA0-9A51-F0E50DCD777CQ27000066-1443DDC2-1264-49A7-974B-393D7D41822DQ27022753-69D7CD03-8A20-4897-9790-AB5A90EE85BEQ27025207-E150D63D-FBD3-4DF2-986F-D0D0F19A9233Q28073374-EED261A2-F2A4-4658-80F1-183E581D013AQ28079063-CF21FEBD-7A69-424E-A80B-4EA0B6ECD151Q28166505-126A3E17-0C1E-48D2-A87D-0E909C826272Q28171273-F0C080FB-5FCC-4FC9-98A0-7AEE0FDD7657Q28212725-C3CACBF1-0A53-426C-A59C-272D0110A3DBQ28248958-D422A041-A30E-474E-AF64-70578496FFC9Q28290774-36360C7F-53AD-487D-B762-9CA82C1CA6B0Q28481562-D0E87225-B598-46C0-87D7-2CB64F702628Q28577591-AAB89E7B-4C14-411D-B116-B0347F6A3416Q30440225-E8131B51-8B42-4F5A-9ECB-989F3395C215Q30443975-92DB1CA1-5ADE-4EF5-BBC2-82CD6462D7D1Q30457479-91095E14-A3CA-4BBC-AAB6-924F230010ABQ30458884-AB2E206B-79A6-4581-BDD4-85C65060284FQ30473378-09C2445E-9689-4722-84B6-9527CC14F3BDQ30490604-13255EC3-99A1-40AB-9657-AFF9F2C7DCC6Q30491310-F7E01CDC-95FE-4018-A3CE-A7252E5859E7Q30497435-D2BE0D71-8145-47B1-9081-85EDF935CEC6Q30541270-65B897DB-87E5-472F-B217-741EBECAA490Q30576714-2031268E-8FF7-4BB8-AF46-4359BB01C47F
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Memantine in moderate-to-severe Alzheimer's disease.
@en
type
label
Memantine in moderate-to-severe Alzheimer's disease.
@en
prefLabel
Memantine in moderate-to-severe Alzheimer's disease.
@en
P2093
P356
P1476
Memantine in moderate-to-severe Alzheimer's disease.
@en
P2093
Albrecht Stöffler
Frederick Schmitt
Hans Jörg Möbius
Memantine Study Group
Rachelle Doody
P304
P356
10.1056/NEJMOA013128
P407
P577
2003-04-01T00:00:00Z